Why DexCom Shares Are Trading Higher Today
Portfolio Pulse from Lekha Gupta
DexCom Inc's shares are trading higher following better-than-expected Q2 FY23 results. The company reported sales of $871.3 million, up 25% Y/Y, beating the consensus of $841.6 million. Adjusted gross profit and operating income also increased. DexCom reported adjusted EPS of $0.34, beating the consensus of $0.23. The company revised its FY23 sales guidance to $3.500 billion-$3.550 billion and raised its outlook for 2025 revenue to $4.6 billion - $5.1 billion.
July 28, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DexCom's better-than-expected Q2 FY23 results and upward revision of its FY23 and 2025 sales guidance are likely to have a positive impact on its stock price in the short term.
DexCom's Q2 FY23 results exceeded expectations, with sales up 25% Y/Y and adjusted EPS beating the consensus. The company also revised its FY23 sales guidance upwards and raised its outlook for 2025 revenue. These positive financial results and optimistic future projections are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100